- Immunotherapies developer for the treatment of cancer Scancell launched an up to £15m equity raising to support potential partnering opportunities, clinical trials and Covid-19 vaccine development.

The fundraising would include a £5m subscription at 5.5p per share by funds managed by Redmile Group, plus a £2m placing and £2m open offer, at the same price.

It would also include a £6m convertible loan notes subscription with a conversion price of 6.2p per share.

Redmile and Vulpes were participating in the loan note issue and Vulpes in the placing.

At 9:04am: [LON:SCLP] Scancell Holdings PLC share price was +0.9p at 7.75p

Story provided by